Sanofi Says Vaccines Getting Back On Track, Rejects M&A
This article was originally published in The Pink Sheet Daily
The company has addressed its vaccine manufacturing issues and is about to resubmit MS therapy Lemtrada to FDA; it reported a 4.7% sales increase in the first quarter, driven by growth in its diabetes and consumer health divisions and Genzyme.
You may also be interested in...
The strong efficacy and sound safety data coming out of the Phase III programs presented at ACC have all eyes on the commercial opportunity for the PCSK9 inhibitor class. Ongoing outcomes trials and market impact of new cholesterol guidelines sparked discussion, and leading sponsors Amgen and Sanofi/Regeneron talked about the potential populations and differences in the devices and dosing of evolocumab and alirocumab.
Rater-blinded design for multiple sclerosis claim netted an approval in Europe but a rejection by FDA, which was concerned about bias related to open label studies.
Emerging Company Profile: Aelix Therapeutics has constructed a potential therapeutic HIV vaccine to refocus the immune system onto vulnerable parts of the virus, and may allow patients to control viral replication without antiretroviral therapy.